CCND1 and urinary bladder cancer: For example, the expression-optimized cutoffs suggest that CCND1 amplifications are overestimated in TCGA head and neck cancer which uses a low threshold (31% vs 18% prevalence) and underestimated in TCGA bladder cancer which uses a high threshold (6% vs 8% prevalence).